Endocyte, Inc. (ECYT) Appoints P. David Mozley, M.D. As Vice President Of Imaging

WEST LAFAYETTE, Ind., April 7, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that P. David Mozley, M.D. has been appointed as vice president of imaging. Dr. Mozley will provide medical and scientific leadership across Endocyte's companion imaging agent portfolio.

"We are excited to welcome Dr. Mozley to our team. He brings a wealth of industry and academic experience in developing novel imaging radiopharmaceuticals and will play a key role at Endocyte as we continue to develop and advance our SMDCs and companion imaging agents," said Ron Ellis, president and chief executive officer of Endocyte.

"I am thrilled to be joining the Endocyte team. We share a commitment to the development of molecular imaging as an ideal modality for patient selection in clinical trials and a tool for practicing physicians to determine how to best treat patients," said Dr. Mozley. "Endocyte's SMDC platform and companion imaging agents epitomize the next frontier in molecular imaging and personalized therapies, and I am greatly looking forward to helping advance and expand Endocyte's pioneering work."

Dr. Mozley has over 25 years of experience using radiopharmaceuticals to diagnose and treat diseases. He is a board-certified physician in nuclear medicine. Prior to joining Endocyte, he served as professor and chief of the Division of Nuclear Medicine at Weill Cornell Medical College and the New York Presbyterian Hospital/Weill Cornell Campus in Manhattan. From 2001 to 2012, Dr. Mozley held multiple positions with progressively increasing responsibilities at Eli Lilly and Merck & Co. While at Merck & Co., he served as senior imaging lead across therapeutic areas for multi-center trials that used imaging as a major endpoint, chaired the PhRMA Imaging group, and co-chaired a technical committee on quantitative imaging for the Radiological Society of North America. He has contributed to the publication of over 100 research reports in the literature on imaging.

Dr. Mozley received his B.S. at the College of William & Mary, Williamsburg, VA, his M.D. from the Brody School of Medicine at East Carolina University, and trained at the University of Pennsylvania in Philadelphia.

About Endocyte

Endocyte is a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company's SMDCs actively target receptors that are expressed or over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly potent drugs into these cells. The companion imaging agents are designed to identify patients whose disease expresses the molecular target of the therapy and who therefore may be more likely to benefit from treatment. For more information, visit http://www.endocyte.com.

CONTACT: Stephanie Ascher Stern Investor Relations, Inc. (212) 362-1200 [email protected]

Suggested Articles

In this week's EuroBiotech Report, Sitryx inks Lilly deal, Genfit downplays COVID-19 impact on NASH data and Gilead tests remdesivir in U.K.

Amgen and new partner Adaptive Biotechnologies are the latest pharma-biotech duo joining forces against the pandemic.

In our EuroBiotech roundup this week, AM-Pharma raises €23 million, Nordic Nanovector makes cuts and Neurimmune, Ethris plan COVID-19 trial.